Abstracts tagged "rheumatoid arthritis (RA) and treatment"

Abstract Number: 946 • 2014 ACR/ARHP Annual Meeting
Phase 1 Study of Immunotherapy Using Autoantigen-Loaded Dendritic Cells in Patients with Anti-Citrullinated Peptide Antigen Positive Rheumatoid Arthritis
Young Bin Joo¹, Jun-Eui Park², Chan-Bum Choi³, Jeongim Choi¹, Jin-ah Jang², Minkyu Heo², Hak-yeop Kim², Hye-Soon Lee⁴, Yong-Soo Bae⁵ and Sang-Cheol Bae¹, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²JW CreaGene Research Institute, JWCreaGene Inc., Seongnam-si, South Korea, ³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁵3Department of Biological Science, Sungkyunkwan University, Suwon, South Korea
Background/Purpose To date, no dendritic cell (DC) immunotherapy has been shown to give a benefit in patients with rheumatoid arthritis (RA). In this prospective phase…
Abstract Number: 2498 • 2014 ACR/ARHP Annual Meeting
Characteristics of Responding Versus Non-Responding Moderate Rheumatoid Arthritis Patients Treated with Etanercept Plus Methotrexate
Josef Smolen¹, David Collier², Annette Szumski³, Heather Jones⁴ and Lisa Marshall⁵, ¹PsAID taskforce, EULAR, Zurich, Switzerland, ²Amgen, Inc., Thousand Oaks, CA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ⁵Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA
Background/Purpose While synthetic or biologic disease-modifying antirheumatic drugs (DMARDs) are often effective, treatment with such agents does not adequately control disease activity in all patients.…
Abstract Number: 398 • 2014 ACR/ARHP Annual Meeting
Anti-Rheumatic Therapy Decreases Syndecan-1 Shedding in Rheumatoid Arthritis (RA)
Ivana Hollan¹, Gunnbjørg Hjeltnes², Torstein Lyberg³, Stefan Agewall³, Allan Wiik⁴, Knut Mikkelsen⁵, Øystein T. Førre⁶, Tram T. Vuong³ and Svein O. Kolset³, ¹Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ²Medicine, Innlandet Hospital Trust, Lillehammer, Norway, ³University of Oslo, Oslo, Norway, ⁴Clinical Biochem/Immunology, Statens Serum Institute, Copenhagen S, Denmark, ⁵Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁶Oslo University Hospital, Oslo, Norway
Background/Purpose Intact glycocalyx is of importance for healthy endothelial function. Changes in the endothelial glycocalyx, characterized by increased levels of circulating syndecan-1, might be related…
Abstract Number: 2492 • 2014 ACR/ARHP Annual Meeting
Does Body Mass Index Impact Long-Term Retention with Abatacept in Patients with RA Who Have Received at Least One Prior Biologic Agent? 2-Year Results from a Real-World, International, Prospective Study
H Nüßlein¹, R Alten², M Galeazzi³, HM Lorenz⁴, MT Nurmohamed⁵, WG Bensen⁶, Gerd Burmester⁷, H-H Peter⁸, P Peichl⁹, K Pavelka¹⁰, M Chartier¹¹, C Poncet¹², C Rauch¹³ and M Le Bars¹⁴, ¹Internistische Schwerpunktpraxis, Nürnberg, Germany, ²Schlosspark-Klinik University Medicine, Berlin, Germany, ³University of Siena, Siena, Italy, ⁴University Hospital, Heidelberg, Germany, ⁵VU Univ Medical Center/Jan van Breeman Research Institute, Amsterdam, Netherlands, ⁶St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ⁷Charité-Universitätsmedizin, Berlin, Germany, ⁸University of Freiburg, Freiburg, Germany, ⁹Evangelisches Krankenhaus, Vienna, Austria, ¹⁰Institute of Rheumatology, Charles University, Prague, Czech Republic, ¹¹Chiltern International, Neuilly, France, ¹²Docs International, Nanterre, France, ¹³Bristol-Myers Squibb, Munich, Germany, ¹⁴Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: In RA, reduced efficacy with anti-TNF therapy1 and dose escalation2 have been reported for obese patients (pts) compared with non-obese pts. Clinical trials have…
Abstract Number: 350 • 2014 ACR/ARHP Annual Meeting
Rho-Associated Protein Kinase (ROCK) Activity Is Elevated in Rheumatoid Arthritis (RA) Patients and May be Responsive to RA Therapies
Reena Khianey¹, Cristina Rozo², Sanjay Gupta³, Vivian P. Bykerk¹, Susan M. Goodman¹ and Alessandra B. Pernis⁴, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²535 East 70th Street, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Research, Hospital for Special Surgery, New York, NY
Background/Purpose: Rho-associated protein kinases (ROCKs) regulate cytoskeletal reorganization and gene expression through protein phosphorylation, and are implicated in the pathogenesis of a wide range of…
Abstract Number: 2441 • 2014 ACR/ARHP Annual Meeting
Prevalence and Determinants of Treatment Adherence Among Patients with Rheumatoid Arthritis
Maria Celeste Orozco¹, Maria Florencia Marengo², Christian A. Waimann², Ana Inés Marcos³, Amelia Granel³, Sofia Velez⁴, Federico Zazzetti⁵, Juan C. Barreira⁶, Paula Kohan⁷, Oscar L. Rillo⁸, María Victoria Collado⁹, Graciela Gómez¹⁰, Ricardo V. Juárez¹¹, Veronica Lencina¹², Andrea D'Orazio¹³, Gustavo Rodriguez Gil¹³, Mariana Salcedo¹⁴ and Gustavo Citera¹⁵, ¹Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Rheumatology, Hospital San Roque de Gonnet, La Plata, La Plata, Argentina, ⁴Rheumatology, Hospital Britanico, Buenos Aires, Argentina, ⁵Hospital Britanico, Buenos Aires, Argentina, ⁶Rheumatology, British Hospital, Buenos Aires, Argentina, ⁷rheumatology, Hospital Gral. de agudos Dr. E. Tornú, Buenos Aires, Argentina, ⁸Rheumatology Unit, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ⁹Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ¹⁰Diaz Colodrero 2537 8° A, Insituto de Investigaciones Medicas de la UBA, Capital Federal, Argentina, ¹¹Rheumatology Section, Hospital Señor del Milagro, Salta, Argentina, ¹²Rheumatology section, Hospital Señor del Milagro, Salta, Argentina, ¹³rheumatology, Hospital Municipal de agudos Dr. Leonidas Lucero, Bahía Blanca, Argentina, ¹⁴Consultorio Privado, San Nicolás, Argentina, ¹⁵Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose : Treatment adherence is a crucial part of successfully managing rheumatic diseases such as Rheumatoid Arthritis (RA). Low adherence to treatment has been related…
Abstract Number: 322 • 2014 ACR/ARHP Annual Meeting
Superior Therapeutic Efficacy of a Novel Oral Small Molecule Retinoic Acid Receptor-Related Orphan Receptor Gamma T [Rorgt] Inverse Agonist Inv-17: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis
Anderson Gaweco^1,2, Samantha Palmer¹, Rambon Shamilov¹, Caroline Stremnitzer¹, Katie Matthews¹, Michael Fisher¹, William Windsor¹, James Blinn¹, Ellen M. Ginzler³ and Jefferson Tilley¹, ¹Innovimmune Biotherapeutics, Brooklyn, NY, ²SUNY-Downstate Medical Center, Brooklyn, NY, ³Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY
Background/Purpose: T helper 17 [TH17] cells and its production of TH17 cytokines IL-17A and IL-17F play a critical role in the pathogenesis of RA and…
Abstract Number: 2411 • 2014 ACR/ARHP Annual Meeting
Assessing Treatment Durability of Infliximab in the Management of Psoriatic Arthritis and Rheumatoid Arthritis Patients in a Canadian Setting
John Kelsall¹, Algis Jovaisas², Proton Rahman³, Dalton Sholter⁴, Michael Starr⁵, William Bensen⁶, Maqbool Sheriff⁷, Wojciech Olszynski⁸, Michel Zummer⁹, Rafat Faraawi¹⁰, Andrew Chow¹¹, Suneil Kapur¹², Emmanouil Rampakakis¹³, John S. Sampalis¹³, Francois Nantel¹⁴, Susan Otawa¹⁵, May Shawi¹⁴ and Allen J Lehman¹⁵, ¹The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ²194 Main Street, University of Ottawa, Ottawa, ON, Canada, ³Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁶St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸University of Saskatchewan, Saskatoon, SK, Canada, ⁹Université de Montréal, Montreal, QC, Canada, ¹⁰Medicine, McMaster University, Hamilton, ON, Canada, ¹¹McMaster University, Hamilton and Credit Valley Hospital, Mississauga, ON, Canada, ¹²Rheumatology, University of Ottawa, Ottawa, ON, Canada, ¹³JSS Medical Research, Montreal, QC, Canada, ¹⁴Janssen Inc., Toronto, ON, Canada, ¹⁵Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The efficacy of anti-TNF in the management of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. The…
Abstract Number: 2037 • 2014 ACR/ARHP Annual Meeting
Incidence and Prevalence of Myasthenia Gravis in Rheumatoid Arthritis Patients with and without Treatment Compared with the General Population
Neil Accortt¹, Mary Anthony¹, Jennifer Schenfeld², Travis Wheeling², Anna Hassebroek², Cynthia O'Malley¹ and Michael Sprafka¹, ¹Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ²Docs Global, Inc, North Wales, PA
Background/Purpose: There is a dearth of information on the incidence rate of myasthenia gravis (MG) in the US and specifically among rheumatoid arthritis (RA) patients. …
Abstract Number: 2034 • 2014 ACR/ARHP Annual Meeting
A Treat-to-Target Strategy Preserves Work Capacity in Early Rheumatoid Arthritis (RA)
Mihir D. Wechalekar¹, Steve Quinn², Susan Lester³, Ella Shanahan⁴, Robert Metcalf⁵, E. Michael Shanahan⁶ and Susanna Proudman^4,7, ¹Flinders University School of Medicine, Adelaide, Australia, ²Flinders Clinical Effectiveness, Flinders University, Adelaide, Australia, ³Rheumatology Unit, Queen Elizabeth Hospital, Woodville South, Australia, ⁴University of Adelaide, Discipline of Medicine, Adelaide, Australia, ⁵University of Adelaide, Adelaide, Australia, ⁶Rheumatology, Flinders University, Bedford Park, South Australia, Australia, ⁷Department of Rheumatology, Royal Adelaide Hospital, SA, Australia
Background/Purpose Historical data (1)indicate a third of patients with RA are unable to work within the first 5 years of diagnosis. Our aim was to…
Abstract Number: 2029 • 2014 ACR/ARHP Annual Meeting
Treatment Patterns of Multimorbid Rheumatoid Arthritis Patients: Results from an International Cross-Sectional Study
Helga Radner^1,2, Kazuki Yoshida^3,4, Ihsane Hmamouchi⁵, Maxime Dougados^6,7, Josef Smolen⁸ and Daniel H Solomon⁹, ¹Department of Internal Medicine III; Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, Kamogawa, Japan, ⁴Division of Rheumatology, Brigham and Women’s Hospital, Boston, MA, ⁵Biostatistics, Epidemiology LBRCE, Mohamed V Souissi University, Rabat, Morocco, ⁶Descartes University, Cochin Hospital, Paris, France, ⁷INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ⁸Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁹Rheumatology, Brigham and Women's Hospital, Boston, MA
Treatment Patterns of Multimorbid Rheumatoid Arthritis Patients: Results from an International Cross-sectional StudyBackground/Purpose The presence of multimorbidity could lead to less intensive treatment of RA.…
Abstract Number: 1456 • 2013 ACR/ARHP Annual Meeting
Golimumab Levels, Anti-Drug Antibodies and Clinical Response In Rheumatoid Arthritis Patients At 28 Week Of Follow-Up
Eva L. Kneepkens¹, Dora pascual-Salcedo², Chamaida Plasencia³, Charlotte L. M. Krieckaert⁴, Desiree van der Kleij⁵, Michael T. Nurmohamed^4,6, Maria Teresa lópez-Casla⁷, Theo Rispens⁸ and Gertjan Wolbink^4,8, ¹Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Immunology unit, La Paz University Hospital, Madrid, Spain, ³Rheumatology, La Paz University Hospital, Madrid, Spain, ⁴Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁵Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁶Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁷Immunology, La Paz University Hospital, Madrid, Spain, ⁸Sanquin Research, Amsterdam, Netherlands
Background/Purpose: Low drug levels of anti-Tumor Necrosis Factor (TNF) therapies are related to poorer response in patients with rheumatoid arthritis (RA). Furthermore, anti-drug antibodies (ADA)…
Abstract Number: 1285 • 2013 ACR/ARHP Annual Meeting
Choline Kinase: A Novel Target For Rheumatoid Arthritis
Monica Guma¹, Elsa Sanchez-Lopez², Alessia Lodi³, Stefano Tiziani⁴, Juan Carlos Lacal⁵, Michael Karin⁶ and Gary S. Firestein⁷, ¹Rheumatology, UCSD School of Medicine, La Jolla, CA, ²Pharmacology, UCSD School of Medicine, La Jolla, CA, ³nutritional Sciences, University of Texas at Austin, Austin, TX, ⁴Nutritional Sciences, University of Texas at Austin, Austin, TX, ⁵Oncology, University Hospital Fundacion Jimenez Diaz, Madrid, Spain, ⁶Departments of Pharmacology, UCSD School of Medicine, La Jolla, CA, ⁷Div of Rheumatology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: Choline kinase (ChoKa) is an essential enzyme for phosphatidylcholine biosynthesis and is required for cell proliferation. The enzyme has also been implicated in cancer…
Abstract Number: 1057 • 2013 ACR/ARHP Annual Meeting
Regional Variations In Rheumatoid Arthritis Treatment and Health Outcomes Across The United States
Susan C. Bolge¹, Roxanne Meyer² and Kathy Annunziata³, ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Janssen Scientific Affairs, LLC, Horsham, NY, ³Kantar Health, Princeton, NJ
Background/Purpose: Current ACR guidelines call for treatment of rheumatoid arthritis (RA) with non-biologic or biologic disease modifying anti-rheumatic drugs (DMARDs). The National Quality Forum has…
Abstract Number: 800 • 2013 ACR/ARHP Annual Meeting
A Strategy For Selecting Individuals With RA For Reduction Of Anti-TNF Therapy Using Combined Clinical and Ultrasound Assessment
Christopher R. Holroyd^1,2, Brian Davidson³, Sarah Bennett³, David Waghorn³, Caron Underhil³, Cyrus Cooper², Antonia Calogeras³, Elaine M. Dennison⁴, Nicholas C. Harvey⁵, Ray Armstrong³, Stephan Gadola⁶ and Christopher J. Edwards^7,8, ¹Rheumatology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ²MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, ³University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ⁴MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, ⁵University of Southampton, MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, ⁶University of Southampton, Southampton, United Kingdom, ⁷NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ⁸University of Southampton, Southampton, United Kingdom
Background/Purpose: Reducing the dose of biological therapy may be possible for patients with rheumatoid arthritis (RA) who have achieved remission or low disease activity (LDA). …

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].